Cantor Fitzgerald Reiterates Overweight on Health Catalyst, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Health Catalyst (NASDAQ:HCAT) and maintained a $16 price target.
September 20, 2024 | 2:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Health Catalyst and maintained a $16 price target, indicating confidence in the company's potential.
The reiteration of an Overweight rating and maintenance of a $16 price target by a reputable analyst suggests a positive outlook for Health Catalyst. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100